A patient with metastatic bile duct cancer — one of the deadliest cancers — has been tumor-free for over 8 years after receiving personalized peptide vaccines that triggered a lasting immune response.
8+ years tumor-freeIn a cancer with typically less than 10% five-year survival for advanced disease, this patient with metastatic cholangiocarcinoma remains tumor-free more than 8 years after personalized peptide vaccination.
What the researchers found
A patient with metastatic intrahepatic cholangiocarcinoma (bile duct cancer) — a typically fatal cancer with few treatment options — has remained tumor-free for more than 8 years after repeated surgery and two successive personalized peptide vaccines. Immune analysis revealed a dominant CD4+ T-cell response against vaccine antigens that persisted for years after the last vaccination, with immune cells infiltrating the tumor site. The patient also developed spontaneous immune responses against tumor neoantigens (CD4+ and CD8+ T cells), which may have contributed to the exceptional outcome. This case highlights both personalized peptide vaccination targeting non-mutated antigens and the central role of CD4+ T cells in antitumor immunity.
Why it matters
Cholangiocarcinoma is one of the most lethal cancers, with 5-year survival rates typically below 10% for advanced disease. This patient's 8+ year tumor-free survival after personalized peptide vaccination is extraordinary and suggests that the immune system can be trained to fight even highly aggressive cancers when given the right peptide targets. The finding that CD4+ T cells — often overshadowed by CD8+ "killer" T cells in cancer immunotherapy — played a dominant role challenges conventional thinking about antitumor immunity.
The numbers in context
8+ years tumor-free · 2 successive personalized peptide vaccines · Dominant CD4+ T-cell response · Tumor neoantigen-specific CD4+ and CD8+ responses detected
How the study worked
This is a long-term follow-up case report of a single patient who received repeated surgery and two personalized peptide vaccines for metastatic intrahepatic cholangiocarcinoma. Researchers performed in-depth functional immune cell analyses to characterize the T-cell responses against vaccine antigens and spontaneous tumor neoantigens, including assessment of tumor-site infiltration and persistence of immune responses over time.
Who was studied
A single patient with metastatic intrahepatic cholangiocarcinoma who received personalized peptide vaccination following repeated surgical interventions
What this study cannot tell us
This is a single-patient case report — the most extreme form of individual evidence. It is impossible to determine from one case whether the peptide vaccines caused the exceptional outcome or whether this patient had unusually favorable biology. The combination of repeated surgery and vaccination makes it difficult to attribute the response to either intervention alone. Case reports of exceptional responders are subject to publication bias, as poor outcomes are rarely reported.
How to read the evidence
This is a single-patient case report — the lowest level of clinical evidence. While the outcome is exceptional and the immunological analysis is thorough, it is impossible to generalize from one case. The result could reflect the vaccines' efficacy, unique patient biology, the surgical interventions, or a combination of all three.
When this study was published
Published in 2025 in the Journal for ImmunoTherapy of Cancer, this case report reflects the current frontier of personalized cancer vaccination. The 8+ year follow-up provides unusually long-term data for this type of intervention.
The bigger picture
Cancer vaccines have long been one of immunotherapy's biggest disappointments — promising in theory but rarely effective in practice. This case, while only one patient, adds to a growing body of evidence that personalized peptide vaccines tailored to individual tumors can generate meaningful and durable immune responses. The emphasis on CD4+ T cells is particularly noteworthy, as most cancer immunotherapy research has focused on CD8+ killer T cells. Understanding how to consistently replicate this kind of response is one of the central challenges in cancer immunology.
Questions still open
- What specific features of this patient's immune system or tumor biology enabled such an exceptional response to peptide vaccination?
- Can personalized peptide vaccines targeting non-mutated antigens achieve similar results in other cholangiocarcinoma patients, or was this an outlier?
- How important was the combination of surgery and vaccination versus vaccination alone in achieving this outcome?
Common questions
What is a personalized peptide vaccine?
Can this approach work for other cancers?
Read the original research
Exceptional tumor-free survival of a patient with metastatic intrahepatic cholangiocarcinoma after surgery and personalized peptide vaccination: revisiting a striking case.
Journal for immunotherapy of cancer, 13(10)
Citation
Maia, Ana; Schuhmacher, Juliane; Nadalin, Silvio; Königsrainer, Alfred; Thiel, Karolin; Nelde, Annika; Zinser, Raphael S; Schroeder, Christopher; Mattern, Sven; Singer, Stephan; Bösmüller, Hans; Rammensee, Hans-Georg; Löffler, Markus W; Gouttefangeas, Cécile. (2025). Exceptional tumor-free survival of a patient with metastatic intrahepatic cholangiocarcinoma after surgery and personalized peptide vaccination: revisiting a striking case.. Journal for immunotherapy of cancer, 13(10). https://doi.org/10.1136/jitc-2025-012107